search
Back to results

A phase4 Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B

Primary Purpose

Chronic Hepatitis B

Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Tenofovir disoproxil 245mg
Tenofovir disoproxil fumarate 300mg
Sponsored by
Samjin Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Hepatitis B

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. As of the date of written consent, adults aged 19 or above
  2. Patients with chronic hepatitis B
  3. For chronic hepatitis B, Viread Tab. monotherapy† for more than 48 weeks, HBV suppression‡(virologic suppression) was confirmed, and it was determined that Tenofovir monotherapy for more than 48 weeks would be required.

    † However, patients who take Viread Tab for more than 48 weeks before screening but do not take Viread Tab at the time of screening and discontinue the administration within 4 weeks until the time of randomization can be registered. (treatment gap ≤ 28 days)

    • HBV DNA < 400 copies/mL (=69 IU/mL*) * IU/mL is converting to copies/mL by unit for each institution. (Ex: 5.8 copies/mL = 1 IU/mL)
  4. Subject who voluntarily consents to participate in the clinical trial and signs an informed consent

Exclusion Criteria:

  1. Patients with liver cancer or decompensated liver cirrhosis* *Cirrhosis with clinical signs/symptoms of decompensation (jaundice, ascites, variceal bleeding, hepatic coma)
  2. Patients with Hepatitis C virus (HCV), human immunodeficiency virus (HIV) with overlapping infections (HCV Ab positive, HIV Ab positive) However, if the HCV Ab or HIV Ab test result is judged to be 'false positive' by the investigator, HCV or HIV infection can be confirmed through additional confirmatory tests (HCV, HIV RNA test), etc.
  3. Patients with other clinically significant liver disease (Hemochromatosis, Wilson's disease, Alcoholic liver disease, Autoimmune hepatitis, α-1 antitrypsin deficiency)
  4. Patients confirmed by laboratory test results as followings

    • Severe anemia: Hemoglobin < 8g/dL ② Inadequate renal function: eGFR (Ccr, Cockcroft-Gault formula) < 50 mL/min ③ Inadequate hepatic function:

      • Total bilirubin > 3.0 mg/dL
      • Albumin < 2.8 mg/dL
      • Prothrombin Time(PT) > INR 2.2
  5. Patients with malignant tumors diagnosed within 5 years prior to screening However, in the case of basal cell carcinoma or squamouscell carcinoma of the skin, it is possible to participate in the clinical trial if it is judged to be 'cured' at the discretion of the investigator after surgery (treatment),.
  6. Patients who are scheduled for an organ transplantation or who have undergone organ transplantation surgery
  7. Patients with a history of clinically significant neuropsychiatric disorders, alcoholism, or drug dependence
  8. Patients known to have hypersensitivity or allergy to components of investigational products or similar drugs
  9. Patients who administered immunosuppressive drugs within 24 weeks prior to screening or who administered systemic corticosteroids over a limited dose (equivalent to prednisolone 10 mg/day) for 4 consecutive weeks or more.
  10. Patients who are expected to require administration of the following drugs during the clinical trial period

    ① Immunosuppressive drug

    ② Systemic corticosteroids above a limited dose (equivalent to prednisolone 10 mg/day) for 2 consecutive weeks or more

    ③ Drugs affecting renal excretion, drugs inducing nephrotoxicity or hepatotoxicity

    ④ Anti-HBV drugs other than Tenofovir (ex. emtricitabine, lamivudine, telbivudine, clevudine, entecavir, interferone)

    ⑤ Patients who administered hepatotonics at a stable dose for more than 3 months before screening can be registered.

  11. Those who have a history of fractures requiring bone mineral density (BMD) monitoring or are at risk of osteopenia, who are judged unable to participate in clinical trials according to the investigator's judgment
  12. For pregnant, lactating and reproductive women, patients who do not consent to contraception by a medically accepted method (surgical sterilization, intrauterine device, condom or diaphragm) during the clinical trial period
  13. Patients who participated in another clinical trial within 12 weeks prior to screening and received investigational drugs or investigational devices.
  14. In addition to the above, subject considered ineligible to participate in this study by the investigator.

Sites / Locations

  • Seoul National University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Experimental group

Control group

Arm Description

Tenolid Tab

Viread Tab

Outcomes

Primary Outcome Measures

Inhibiting† rate of HBV virus at 48 weeks after baseline †HBV DNA < 400 copies/mL (=69 IU/mL*) *IU/mL is converting to copies/mL by unit for each institution. (ex: 5.8 copies/mL = 1 IU/mL)

Secondary Outcome Measures

Inhibiting† rate of HBV virus at 12, 24 and 36 weeks after baseline †HBV DNA < 400 copies/mL (=69 IU/mL*) * IU/mL is converting to copies/mL by unit for each institution. (ex: 5.8 copies/mL = 1 IU/mL)
Undetected‡ rate of HBV virus at 12, 24, 36 and 48 weeks after baseline ‡ The lower limit of quantification (LLOQ) for each institution is used, and if it is less than the LLOQ, the HBV DNA level is set to '0'.
Change of HBV DNA(log10 copies/mL) at 12, 24, 36 and 48 weeks from baseline
Loss rate of HBeAg in HBeAg(+) patients at 12, 24, 36 and 48 weeks after baseline
Seroconversion† rate of HBeAg in HBeAg(+) patients at 12, 24, 36 and 48 weeks after baseline †Generation of anti-HBe
Loss rate of HBsAg in HBsAg(+) patients at 12, 24, 36 and 48 weeks after baseline
Seroconversion† rate of HBsAg in HBsAg(+) patients at 12, 24, 36 and 48 weeks after baseline †Generation of anti-HBs
Normal rate of ALT at 12, 24, 36 and 48 weeks after baseline
Change of ALT at 12, 24, 36 and 48 weeks from baseline
Virologic breakthrough* rate within 48 weeks after baseline *HBV DNA ≥ 400 copies/mL: twice in a row at intervals of 2 weeks or more or HBV DNA levels: increasing by 1log10 from Nadir levels of each subject twice in a row (HBV DNA <400 copies/mL)

Full Information

First Posted
February 25, 2022
Last Updated
March 21, 2022
Sponsor
Samjin Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05282407
Brief Title
A phase4 Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B
Official Title
A Multi-Center, Randomized, Open-label, Parallel, Active-controlled, Non-inferiority, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of Switching to Tenolid Tab From Viread Tab in Chronic Hepatitis B Patients on Treatment With Tenofovir Disoproxil Fumarate
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
November 20, 2017 (Actual)
Primary Completion Date
April 17, 2019 (Actual)
Study Completion Date
April 17, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Samjin Pharmaceutical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a Phase4, multicenter, open-label, randomized study to demonstrate that the Tenolid Tab switching group is non-inferior to the virologic suppression effect compared to the Viread Tab continuous administration group and evaluate the safety of Tenolid Tab. This clinical trial was conducted on patients who were taking Viread Tab as monotherapy for more than 48 weeks for chronic hepatitis B. At the time of screening(Visit 1), information on factors related to medical history and prognosis including Viread Tab administration were collected retrospectively from the subjects who voluntarily signed the informed consent form (ICF). Only subjects who are determined to be suitable for the study eligibility(inclusion/exclusion) criteria as a result of the screening evaluations are randomized in a 1:1 ratio to one of the two groups at the baseline. Subjects will receive investigational product start on the next day of randomization for 48 weeks. Subjects will visit to the study site on 12, 24, 36, 24 weeks after starting dosing investigational product and evaluated for effectiveness of virologic suppression and safety.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Hepatitis B

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
118 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental group
Arm Type
Experimental
Arm Description
Tenolid Tab
Arm Title
Control group
Arm Type
Active Comparator
Arm Description
Viread Tab
Intervention Type
Drug
Intervention Name(s)
Tenofovir disoproxil 245mg
Intervention Description
1 tablet q.d. for 48 weeks
Intervention Type
Drug
Intervention Name(s)
Tenofovir disoproxil fumarate 300mg
Intervention Description
1 tablet q.d. for 48 weeks
Primary Outcome Measure Information:
Title
Inhibiting† rate of HBV virus at 48 weeks after baseline †HBV DNA < 400 copies/mL (=69 IU/mL*) *IU/mL is converting to copies/mL by unit for each institution. (ex: 5.8 copies/mL = 1 IU/mL)
Time Frame
48 weeks
Secondary Outcome Measure Information:
Title
Inhibiting† rate of HBV virus at 12, 24 and 36 weeks after baseline †HBV DNA < 400 copies/mL (=69 IU/mL*) * IU/mL is converting to copies/mL by unit for each institution. (ex: 5.8 copies/mL = 1 IU/mL)
Time Frame
12, 24, and 36 weeks
Title
Undetected‡ rate of HBV virus at 12, 24, 36 and 48 weeks after baseline ‡ The lower limit of quantification (LLOQ) for each institution is used, and if it is less than the LLOQ, the HBV DNA level is set to '0'.
Time Frame
12, 24, 36 and 48 weeks
Title
Change of HBV DNA(log10 copies/mL) at 12, 24, 36 and 48 weeks from baseline
Time Frame
12, 24, 36 and 48 weeks
Title
Loss rate of HBeAg in HBeAg(+) patients at 12, 24, 36 and 48 weeks after baseline
Time Frame
12, 24, 36 and 48 weeks
Title
Seroconversion† rate of HBeAg in HBeAg(+) patients at 12, 24, 36 and 48 weeks after baseline †Generation of anti-HBe
Time Frame
12, 24, 36 and 48 weeks
Title
Loss rate of HBsAg in HBsAg(+) patients at 12, 24, 36 and 48 weeks after baseline
Time Frame
12, 24, 36 and 48 weeks
Title
Seroconversion† rate of HBsAg in HBsAg(+) patients at 12, 24, 36 and 48 weeks after baseline †Generation of anti-HBs
Time Frame
12, 24, 36 and 48 weeks
Title
Normal rate of ALT at 12, 24, 36 and 48 weeks after baseline
Time Frame
12, 24, 36 and 48 weeks
Title
Change of ALT at 12, 24, 36 and 48 weeks from baseline
Time Frame
12, 24, 36 and 48 weeks
Title
Virologic breakthrough* rate within 48 weeks after baseline *HBV DNA ≥ 400 copies/mL: twice in a row at intervals of 2 weeks or more or HBV DNA levels: increasing by 1log10 from Nadir levels of each subject twice in a row (HBV DNA <400 copies/mL)
Time Frame
48 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: As of the date of written consent, adults aged 19 or above Patients with chronic hepatitis B For chronic hepatitis B, Viread Tab. monotherapy† for more than 48 weeks, HBV suppression‡(virologic suppression) was confirmed, and it was determined that Tenofovir monotherapy for more than 48 weeks would be required. † However, patients who take Viread Tab for more than 48 weeks before screening but do not take Viread Tab at the time of screening and discontinue the administration within 4 weeks until the time of randomization can be registered. (treatment gap ≤ 28 days) HBV DNA < 400 copies/mL (=69 IU/mL*) * IU/mL is converting to copies/mL by unit for each institution. (Ex: 5.8 copies/mL = 1 IU/mL) Subject who voluntarily consents to participate in the clinical trial and signs an informed consent Exclusion Criteria: Patients with liver cancer or decompensated liver cirrhosis* *Cirrhosis with clinical signs/symptoms of decompensation (jaundice, ascites, variceal bleeding, hepatic coma) Patients with Hepatitis C virus (HCV), human immunodeficiency virus (HIV) with overlapping infections (HCV Ab positive, HIV Ab positive) However, if the HCV Ab or HIV Ab test result is judged to be 'false positive' by the investigator, HCV or HIV infection can be confirmed through additional confirmatory tests (HCV, HIV RNA test), etc. Patients with other clinically significant liver disease (Hemochromatosis, Wilson's disease, Alcoholic liver disease, Autoimmune hepatitis, α-1 antitrypsin deficiency) Patients confirmed by laboratory test results as followings Severe anemia: Hemoglobin < 8g/dL ② Inadequate renal function: eGFR (Ccr, Cockcroft-Gault formula) < 50 mL/min ③ Inadequate hepatic function: Total bilirubin > 3.0 mg/dL Albumin < 2.8 mg/dL Prothrombin Time(PT) > INR 2.2 Patients with malignant tumors diagnosed within 5 years prior to screening However, in the case of basal cell carcinoma or squamouscell carcinoma of the skin, it is possible to participate in the clinical trial if it is judged to be 'cured' at the discretion of the investigator after surgery (treatment),. Patients who are scheduled for an organ transplantation or who have undergone organ transplantation surgery Patients with a history of clinically significant neuropsychiatric disorders, alcoholism, or drug dependence Patients known to have hypersensitivity or allergy to components of investigational products or similar drugs Patients who administered immunosuppressive drugs within 24 weeks prior to screening or who administered systemic corticosteroids over a limited dose (equivalent to prednisolone 10 mg/day) for 4 consecutive weeks or more. Patients who are expected to require administration of the following drugs during the clinical trial period ① Immunosuppressive drug ② Systemic corticosteroids above a limited dose (equivalent to prednisolone 10 mg/day) for 2 consecutive weeks or more ③ Drugs affecting renal excretion, drugs inducing nephrotoxicity or hepatotoxicity ④ Anti-HBV drugs other than Tenofovir (ex. emtricitabine, lamivudine, telbivudine, clevudine, entecavir, interferone) ⑤ Patients who administered hepatotonics at a stable dose for more than 3 months before screening can be registered. Those who have a history of fractures requiring bone mineral density (BMD) monitoring or are at risk of osteopenia, who are judged unable to participate in clinical trials according to the investigator's judgment For pregnant, lactating and reproductive women, patients who do not consent to contraception by a medically accepted method (surgical sterilization, intrauterine device, condom or diaphragm) during the clinical trial period Patients who participated in another clinical trial within 12 weeks prior to screening and received investigational drugs or investigational devices. In addition to the above, subject considered ineligible to participate in this study by the investigator.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yoon Jun Kim, Ph.D.
Organizational Affiliation
Seoul National University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

A phase4 Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B

We'll reach out to this number within 24 hrs